Diagnostic Evaluation in Allergic Urticaria

Basic Diagnostic Approach

• The American Academy of Allergy, Asthma, and Immunology recommends a detailed history and physical examination, including reviewing photographs of urticaria lesions, as the primary diagnostic approach 1, 2

Laboratory Tests for Chronic Urticaria

• The European Academy of Allergology and Clinical Immunology suggests that useful screening tests for chronic urticaria include complete blood count and differential count 3, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) 2, total IgE level 2, and IgG-anti-thyroid peroxidase (TPO) level [1] [2]
• The British Association of Dermatologists recommends that lezyon biopsy is essential to histologically confirm small vessel vasculitis in suspected urticarial vasculitis 3

Specialized Tests

• The American Academy of Allergy, Asthma, and Immunology proposes that autoimmuno/allergic urticaria evaluation should include total IgE and IgG-anti-TPO ratio, which is the best surrogate marker for autoimmune chronic spontaneous urticaria 1, 2
• The European Academy of Allergology and Clinical Immunology states that low or very low total IgE and high IgG-anti-TPO levels are seen in autoimmune urticaria 2
• The British Association of Dermatologists recommends that C4 level has high sensitivity and low specificity for C1 inhibitor deficiency, and if low, C1 inhibitor deficiency can be confirmed with quantitative and functional C1 inhibitor tests 3

Urticaria in Children: Clinical Presentation and Diagnosis

Clinical Characteristics

• The British Journal of Dermatology recommends that individual wheals in ordinary urticaria last 2-24 hours before resolving without scarring 4
• Ordinary urticaria is characterized by wheals lasting 2-24 hours per wheal 4
• Contact urticaria typically lasts up to 2 hours 4
• Physical urticaria usually resolves within 1 hour, except for delayed pressure urticaria 4
• Delayed pressure urticaria develops in 2-6 hours and fades within 48 hours 4
• Urticarial vasculitis is distinguished by weals persisting for days 4
• Weals persisting beyond 24 hours suggest urticarial vasculitis 4

Diagnostic Approach

• The diagnosis of urticaria is primarily clinical, and investigations should be guided by history and not performed routinely in all patients 4
• No investigations are required for acute/episodic urticaria except where suggested by history 4
• IgE-mediated reactions can be confirmed by skin-prick testing and CAP fluoroimmunoassay when environmental allergens are suspected 4
• For chronic urticaria, useful screening includes full blood count and white cell differential, erythrocyte sedimentation rate, and thyroid autoantibodies and thyroid function tests 4
• Autologous serum skin test (ASST) offers a reasonably sensitive and specific screening test for histamine-releasing autoantibodies in experienced centers 4

Management of Acute Urticaria in Young Children

Initial Assessment

• Acute urticaria in children is diagnosed on clinical grounds; routine laboratory testing is not required unless the history points to a specific trigger. 5
• Relevant history should include recent exposure to common food allergens (e.g., nuts, fish, eggs, milk) and contact with latex or chemicals, as these are frequent precipitants in this age group. 5
• When a specific IgE‑mediated allergy is suspected, skin‑prick testing or specific IgE (CAP) assays may be performed, but results must be interpreted in the clinical context. 5

First‑Line Pharmacologic Therapy

• A non‑sedating H1 antihistamine at the standard pediatric dose is the cornerstone of treatment; the exact formulation and dose must be verified against the product data sheet because age‑related restrictions vary for children under 12 years. 6, 7
• No licensed H1 antihistamine is contraindicated in children ≥12 years, but for younger children the choice of agent must be individualized based on the product’s age‑specific labeling. 6, 7, 8

Adjunctive Measures

• A short‑course of oral corticosteroids (lower than the adult regimen of 50 mg daily for 3 days) can shorten the duration of an acute episode in children. 6, 7, 8
• Topical cooling agents such as calamine lotion or 1 % menthol in an aqueous cream provide symptomatic itch relief. 5
• Patients should avoid known aggravating factors—overheating, emotional stress, and alcohol exposure—as these can exacerbate urticaria. 5
• Aspirin and other NSAIDs should be avoided because they may provoke mast‑cell degranulation and worsen urticaria. 5

Emergency Management

• Laryngeal angio‑edema or anaphylaxis mandates immediate intramuscular epinephrine administration. 6, 7, 8
• For children weighing approximately 15–30 kg (the typical weight range for an 18‑month‑old), a fixed‑dose 150 µg epinephrine autoinjector is recommended. 6, 7, 8
• Parenteral hydrocortisone may be given as an adjunct for severe laryngeal edema, recognizing that its therapeutic effect is delayed. 6, 7, 8
• If there is no significant improvement after the first epinephrine dose, a second dose should be administered. 6, 7, 8
• Consider prescribing an epinephrine autoinjector for home use when the child’s history indicates a risk of recurrent life‑threatening attacks. 6, 7, 8

Common Pitfalls

• Extensive laboratory work‑ups are unnecessary for typical acute urticaria and do not add clinical value. 5
• Long‑term oral corticosteroids should be avoided; they are reserved only for selected severe cases under specialist supervision. 6, 7, 8
• Adding an H2 antihistamine to an H1 agent may improve control in some patients, but the supporting evidence is limited and the benefit is mainly for associated dyspepsia. 6

Evidence‑Based Management of Acute Migratory Urticaria in Children

Diagnosis and Initial Assessment

• Clinical diagnosis is sufficient for typical acute urticaria; routine laboratory testing is unnecessary unless the history suggests a specific trigger. 9, 10
• Individual wheals in ordinary acute urticaria resolve within 2–24 hours without leaving scars, a pattern that helps differentiate it from urticarial vasculitis, where lesions persist for days. 10, 9
• Physical factors such as overheating, pressure, cold exposure, or exercise can provoke or aggravate urticaria lesions. 9, 10

First‑Line Pharmacologic Treatment

• Second‑generation H1 antihistamines constitute the cornerstone of therapy for acute pediatric urticaria. 11
• Approximately 40 % of children achieve adequate symptom control with antihistamine monotherapy. 11
• Short‑course oral corticosteroids (lower than adult regimens) may be used to shorten episode duration when urticaria is severe or when antihistamines alone are insufficient; they should be limited to brief courses and avoided for long‑term use. 11

Adjunctive and Preventive Measures

• Aspirin and non‑steroidal anti‑inflammatory drugs (NSAIDs) can trigger mast‑cell degranulation and worsen urticaria; they should be avoided in affected children. 10
• When an environmental allergen is suspected, IgE‑mediated sensitization can be confirmed with skin‑prick testing or specific IgE assays. 9

Prognosis and Follow‑Up

• A substantial proportion of acute urticaria cases remain idiopathic, with no identifiable cause despite thorough evaluation. 9, 10
• Persistence of wheals beyond 24 hours should raise suspicion for urticarial vasculitis, prompting consideration of a skin biopsy for definitive diagnosis. 9, 10

Key Clinical Features and Diagnostic Approach for Urticaria and Its Mimics

Duration and Morphology of Wheals

Urticarial Vasculitis

Angioedema Without Wheals

Contact Urticaria

Physical Urticarias

Investigation Strategy for Chronic Urticaria and Mimics

Evidence‑Based Clinical Features and Multidisciplinary Recommendations for Urticarial Vasculitis

Clinical Features Suggestive of Urticarial Vasculitis

• Painful or burning skin lesions, rather than purely itchy wheals, are a strong indicator of urticarial vasculitis. [Level of evidence not specified] 14
• Persistent wheals that leave residual hyperpigmentation, ecchymosis, or purpura after resolution signify underlying vascular damage and should raise suspicion for urticarial vasculitis. [Level of evidence not specified] 14

Recommended Specialist Consultations

• Patients with suspected urticarial vasculitis should be referred to rheumatology for evaluation of systemic lupus erythematosus overlap and management of joint or systemic manifestations. [Level of evidence not specified] 14
• When a paraneoplastic syndrome is considered, a hematology‑oncology consultation is advised to assess for underlying malignancy. [Level of evidence not specified] 14

Hereditary Angioedema (HAE): Evidence‑Based Diagnostic and Management Guidelines

Epidemiology & Clinical Presentation

• Approximately half of individuals with HAE experience their first swelling episode before age 10, and symptom severity often increases around puberty【15】.
• Typical attacks are non‑pruritic, non‑pitting angioedema that progress over ~24 hours and resolve within 48–72 hours【15】.
• Minor mechanical trauma (e.g., venipuncture) is a well‑recognized trigger for HAE attacks【15】.

Diagnostic Testing

• Serum C4 concentration is low in >95 % of patients with HAE both during attacks and in remission, making it a reliable screening test【15】.
• Type I HAE (≈85 % of cases) is defined by low C1‑inhibitor antigen levels and reduced functional activity【15】【16】.
• Type II HAE (≈15 % of cases) shows normal or elevated C1‑inhibitor antigen with persistently low functional activity【15】【16】.

Pathophysiology

• Deficiency or dysfunction of C1‑inhibitor leads to unchecked bradykinin production, which increases vascular permeability and causes tissue swelling【15】.
• Mechanical trauma such as venipuncture activates the contact (Hageman factor) pathway, generating excess bradykinin locally【15】.

Acute Attack Management

• Antihistamines, systemic corticosteroids, and epinephrine are ineffective for HAE because the edema is mediated by bradykinin rather than histamine or IgE pathways【15】.
• First‑line on‑demand therapies include:
  
  • Plasma‑derived C1‑inhibitor concentrate,
  • Icatibant (bradykinin‑B2 receptor antagonist), and
  • Ecallantide (plasma kallikrein inhibitor)【16】.
• Laryngeal edema can be fatal; early recognition of throat tightness, hoarseness, or dysphagia should prompt immediate emergency response【15】.
• In airway emergencies, administer C1‑inhibitor concentrate at 20 U/kg and prepare for possible endotracheal intubation【16】.

Genetic Considerations

• HAE follows an autosomal dominant inheritance pattern, conferring a 50 % transmission risk to each offspring of an affected parent【15】.
• Approximately 25 % of cases arise from de novo SERPING1 mutations, so a negative family history does not exclude the diagnosis【15】.

Long‑Term and Peri‑Procedural Prophylaxis

• Long‑term prophylaxis options include attenuated androgens (e.g., danazol, stanozolol) or regular administration of plasma‑derived C1‑inhibitor concentrate【16】.
• Short‑term prophylaxis before high‑risk procedures (dental work, surgery) can be achieved with a pre‑procedure dose of C1‑inhibitor concentrate or tranexamic acid【16】.

Referral & Specialist Care

• Patients suspected of having HAE should be referred promptly to an allergist/immunologist experienced in HAE for definitive diagnosis, individualized treatment planning, and family screening【15】.

Diagnostic and Laboratory Guidelines for Differentiating Leukocytoclastic Vasculitis and Urticarial Vasculitis

Histopathology

• A lesional skin biopsy is required to confirm small‑vessel vasculitis when wheals persist > 24 hours or when palpable purpuric lesions are present, because both entities share the hallmark of leukocytoclastic vasculitis on histology. 17
• The characteristic microscopic pattern includes fibrinoid necrosis of vessel walls, neutrophil‑rich perivascular infiltrates with nuclear fragmentation (leukocytoclasia), endothelial damage, perivascular fibrin deposition, and red‑blood‑cell extravasation. 17

Laboratory Evaluation

• Serum complement testing (C3, C4) should be performed in any case of suspected urticarial vasculitis to differentiate normocomplementemic from hypocomplementemic disease. 17
• Hypocomplementemic urticarial vasculitis—identified by low C4 and the presence of anti‑C1q autoantibodies—is associated with a poorer prognosis and a higher likelihood of systemic involvement (e.g., McDuffie syndrome). 17
• Complement levels are not routinely measured in the work‑up of classic leukocytoclastic vasculitis unless urticarial vasculitis is being considered. 17
• Both conditions warrant a comprehensive vasculitis screen that includes complete blood count, renal function and urinalysis, hepatitis B/C serology, antinuclear antibodies, ANCA, and IgA staining on biopsy specimens. 17
• Inflammatory markers (ESR or CRP) are typically elevated in leukocytoclastic and urticarial vasculitis, helping to distinguish them from ordinary urticaria where these markers are normal. 17

Prognostic Indicators

• The complement status of urticarial vasculitis predicts outcome: normocomplementemic disease generally follows a benign, cutaneous course, whereas hypocomplementemia signals a higher risk of systemic disease and a worse prognosis. 17

Clinical Pitfalls (Diagnostic Safeguards)

• Persistent wheals lasting > 24 hours must not be dismissed as ordinary urticaria; this temporal feature mandates skin biopsy to exclude urticarial vasculitis. 17
• Complement testing should not be omitted once urticarial vasculitis is confirmed, because hypocomplementemia identifies patients at increased risk for systemic involvement. 17
• Systemic symptoms such as fever, arthralgia, abdominal pain, or renal dysfunction should prompt a full vasculitis work‑up and possible rheumatology referral. 17